Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 4/20 | 0.48 |
| ▸ | FPR2 | P25090 | 4/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3954506 | 0.92 | EPHX2 (0.46) | FPR1FPR2EPHX1EPHX2 | |
| SCHEMBL3953261 | 0.90 | EPHX2 (0.41) | FPR1FPR2EPHX1EPHX2SMN1; SMN2 | |
| SCHEMBL3955787 | 0.88 | NPC1 (0.43) | FPR1FPR2EPHX1EPHX2SMN1; SMN2 | |
| SCHEMBL3951491 | 0.88 | RAB9A (0.44) | FPR1FPR2SMN1; SMN2MEN1HTT | |
| SCHEMBL3955059 | 0.85 | RAB9A (0.43) | CNR1SMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL3953270 | 0.81 | RAB9A (0.44) | EPHX2CNR1SMN1; SMN2MEN1HTT | |
| SCHEMBL3958772 | 0.80 | NPC1 (0.44) | FPR1FPR2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3955061 | 0.76 | CNR1 (0.43) | EPHX2CNR1SMN1; SMN2MEN1HTT | |
| SCHEMBL4158829 | 0.73 | SLC6A2 (0.40) | FPR1SMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL3950790 | 0.73 | TRPV1 (0.39) | SMN1; SMN2MEN1KMT2AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009032754-A2 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032754-A2 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | FPR1 394/4885FPR2 640/4885EPHX1 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.